ConvaTec Group PLC
LSE:CTEC
Intrinsic Value
ConvaTec Group Plc operates as holding company, which engages in medical business. [ Read More ]
The intrinsic value of one
CTEC
stock under the Base Case scenario is
321.96
GBX.
Compared to the current market price of 257.8 GBX,
ConvaTec Group PLC
is
Undervalued by 20%.
ConvaTec Group PLC's market capitalization is 5.3B GBX.
CTEC stock price is 257.8 GBX.
CTEC stock price (257.8 GBX) is 20% less than its Intrinsic Value (321.96 GBX).
CTEC stock price (257.8 GBX) is 43% less than its Relative Value (449.8 GBX). Open Relative Valuation
CTEC has upside potential of 19% compared to the average analyst price target.
Open Wall St Estimates
CTEC's ROE (Return on Equity) has increased in the last 3 years from 7% to 8%.
CTEC's Revenue has grown by 3% over the past 12 months.
CTEC's ROE (Return on Equity) for the past 12 months is positive and is equal to 8%.
CTEC's Revenue has been growing by 4% per year for the last 3 years.
CTEC's Revenue is forecast to grow at a rate of 6% per year over the next 3 years.
CTEC has positive three-year average ROIC (Return on Invested Capital): 13%. The company is efficient at using invested capital to generate operating income.
CTEC has positive Net Income for the last twelve months.
CTEC has positive three-year average ROE (Return on Equity): 6%. The company is efficient at transforming stockholders' equity into net income.
CTEC's short-term assets (870m USD) exceed its short-term liabilties (536m USD).
CTEC has positive Operating Income for the last twelve months.
CTEC's D/E (Debt to Equity) is very low and is equal to 0.76.
CTEC has positive Free Cash Flow for the last twelve months.
CTEC's long-term assets (4B USD) exceed its long-term liabilties (2B USD).
CTEC's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from 5% to 61%.
CTEC's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 61%.
CTEC has positive Gross Profit for the last twelve months.
CTEC has positive Net Debt. This means that the company has more debt (1B USD) than cash and short-term investments (98m USD).
CTEC's Altman Z-Score is very high and is equal to 4.86.
CTEC earns more than enough operating income (2B USD) to safely cover interest payments on its debt (71m USD).
Valuation Backtest
ConvaTec Group PLC
Run backtest to discover the historical profit from buying and selling
CTEC
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
ConvaTec Group PLC
Balance Sheet Decomposition
ConvaTec Group PLC
| Current Assets | 870m |
| Cash & Short-Term Investments | 97.6m |
| Receivables | 350.2m |
| Other Current Assets | 422.2m |
| Non-Current Assets | 2.8B |
| Long-Term Investments | 22.9m |
| PP&E | 548.5m |
| Intangibles | 2.2B |
| Other Non-Current Assets | 38.2m |
| Current Liabilities | 536.4m |
| Accounts Payable | 388.7m |
| Other Current Liabilities | 147.7m |
| Non-Current Liabilities | 1.5B |
| Long-Term Debt | 1.3B |
| Other Non-Current Liabilities | 192.9m |
Earnings Waterfall
ConvaTec Group PLC
|
Revenue
|
2.1B
USD
|
|
Cost of Revenue
|
1.3B
USD
|
|
Gross Profit
|
3.4B
USD
|
|
Operating Expenses
|
-935.4m
USD
|
|
Operating Income
|
2.5B
USD
|
|
Other Expenses
|
-2.3B
USD
|
|
Net Income
|
130.3m
USD
|
Free Cash Flow Analysis
ConvaTec Group PLC
CTEC Profitability Score
Profitability Due Diligence
ConvaTec Group PLC's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
Score
ConvaTec Group PLC's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
CTEC Solvency Score
Solvency Due Diligence
ConvaTec Group PLC's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Score
ConvaTec Group PLC's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CTEC Price Targets Summary
ConvaTec Group PLC
According to Wall Street analysts, the average 1-year price target for
CTEC
is 307.25 GBX
with a low forecast of 222.2 GBX and a high forecast of 378.12 GBX.
Shareholder Return
CTEC Price
ConvaTec Group PLC
| Average Annual Return | 17.9% |
| Standard Deviation of Annual Returns | 21.78% |
| Max Drawdown | -12% |
| Market Capitalization | 5.3B GBX |
| Shares Outstanding | 2 049 789 952 |
| Percentage of Shares Shorted | 150% |
Company Profile
ConvaTec Group PLC
Country
Industry
Market Cap
Dividend Yield
Description
ConvaTec Group Plc operates as holding company, which engages in medical business. The company is headquartered in Reading, Berkshire and currently employs 10,025 full-time employees. The company went IPO on 2016-10-26. The firm focuses on therapies for the management of chronic conditions, including products used for advanced chronic and acute wound care, ostomy care, continence and critical care and infusion devices used in the treatment of diabetes and other conditions. The company provides InnovaMatrixAC and InnovaBurn. The company markets and sell its solutions and services in four categories, such as Advanced Wound Care, Ostomy Care, Continence and Critical Care, and Infusion Care. Its Advanced Wound Care (AWC) is an Advanced dressing for the management of acute and chronic wounds resulting from ongoing conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. Its Ostomy Care provides devices, accessories and services for people with a stoma (a surgically created opening where bodily waste is discharged), commonly resulting from causes such as colorectal cancer, inflammatory bowel disease and bladder cancer.
Contact
IPO
Employees
Officers
The intrinsic value of one
CTEC
stock under the Base Case scenario is
321.96
GBX.
Compared to the current market price of 257.8 GBX,
ConvaTec Group PLC
is
Undervalued by 20%.
You don't have any saved screeners yet
